Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

SIMPLE SUMMARY: Thus far, clinical studies have shown that immunotherapy (atezolizumab-bevacizumab) has shown better and favorable overall survival than sorafenib for advanced hepatocellular carcinoma (HCC). However, the treatment outcomes of hepatic arterial infusion chemotherapy (HAIC) with cispla...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaizen, Yuki, Nakano, Masahito, Fukumori, Kazuta, Yano, Yoichi, Takaki, Kota, Niizeki, Takashi, Kuwaki, Kotaro, Fukahori, Masaru, Sakaue, Takahiko, Yoshimura, Sohei, Nakazaki, Mika, Kuromatsu, Ryoko, Okamura, Shusuke, Iwamoto, Hideki, Shimose, Shigeo, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Koga, Hironori, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582478/
https://www.ncbi.nlm.nih.gov/pubmed/34771452
http://dx.doi.org/10.3390/cancers13215282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582478/
https://www.ncbi.nlm.nih.gov/pubmed/34771452
http://dx.doi.org/10.3390/cancers13215282

Ejemplares similares